Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2017 | 73 | 07 |
Tytuł artykułu

Odporność humoralna u cieląt szczepionych eksperymentalnie przeciwko zakażeniom Mycoplasma bovis

Treść / Zawartość
Warianty tytułu
Humoral immunity in the calves experimentally vaccinated against Mycoplasma bovis infections
Języki publikacji
The object of the study was to evaluate the effect of an experimental vaccine against Mycoplasma bovis infections on selected humoral immune parameters in the calves. The study was carried out on twelve calves divided into two equal groups: experimental and control. The experimental calves were subcutaneously injected with experimental vaccine composed of suspension of the M. bovis field strain of with saponin and lysozyme. The control group was administered with PBS by the same route. Blood samples for laboratory analyses were collected from all the animals directly prior to the proper experiment (zero test), then at daily intervals up to the 7th day of observation and next at weekly ones up to the 12th week after the vaccination. Serum samples were examined for total bovine immunoglobulins (Ig) and their individual classes (IgG, A i M) using suitable ELISA kits. In response to the vaccine the total serum concentration of Ig was at first lower than in the control animals up to the 56th day of observation, then it increased up to the end of the study. A distinct stimulation of the IgG synthesis was observed in the experimental animals throughout the study with the exception of the 42nd and 77th days when it was slightly decreased. On the other hand the IgA concentration was considerably lower in the experimental calves when compared to the control up to the 7th day of observation, whereas it was visibly increased at day 63rd and 70th after the vaccination. In response to the vaccination the IgM concentration had comparable values to the control throughout the study with the exception of the 4th and 56th days when they were considerably higher, whereas the IgM decrease was observed only at the 21st day after the vaccination. The experimental vaccine composed of the field strain of M. bovis with saponin and lysozyme caused significant activation of selected indices of humoral immunity in the affected animals.
Opis fizyczny
  • Zakład Chorób Bydła i Owiec, Państwowy Instytut Weterynaryjny - Państwowy Instytut Badawczy w Puławach , Al.Partyzantów 57, 24-100 Puławy
  • Zakład Chorób Bydła i Owiec, Państwowy Instytut Weterynaryjny - Państwowy Instytut Badawczy w Puławach , Al.Partyzantów 57, 24-100 Puławy
  • Ayling R. D., Rosales R. S., Barden G., Gosney F. L.: Changes in antimicrobial susceptibility of Mycoplasma bovis isolates from Great Britain. Vet. Rec. 2014, 175, 486.
  • Barret D. C.: Cost-effective antimicrobial drug selection for the management and control of respiratory disease in European cattle. Vet. Rec. 2000, 146, 545-550.
  • Bednarek D., Dudek K.: Acute phase proteins in the calves administered with experimental M. bovis vaccine. World Buiatrics Congress, Dublin 2016, P02-002-144, 423.
  • Bednarek D., Dudek K.: Flow cytometry analysis in the calves experimentally vaccinated against Mycoplasma bovis infection. European Buiatrics Forum, Rome 2015, 133.
  • Dudek K., Bednarek D.: Last survey of Mycoplasma bovis prevalence in Polish cattle affected with respiratory syndrome. Bull. Vet. Inst. Pulawy 2012, 56, 447-451.
  • Dudek K., Bednarek D., Ayling R. D., Kycko A., Szacawa E., Karpińska T. A.: An experimental vaccine composed of two adjuvants gives protection against Mycoplasma bovis in calves. Vaccine 2016, 34, 3051-3058.
  • Dudek K., Bednarek D., Szacawa E.: Evaluation of immune response in seropositive cattle for Mycoplasma bovis. Bull. Vet. Inst. Pulawy 2011, 55, 631-634.
  • Houlihan M. G., Veenstra B., Christian M. K., Nicholas R., Ayling R.: Mastitis and arthritis in two dairy herds caused by Mycoplasma bovis. Vet. Rec. 2007, 160, 126-127.
  • Howard C. J., Taylor G., Collins J., Gourlay R. N.: Interaction of Mycoplasma dispar and Mycoplasma agalactiae subsp. bovis with bovine alveolar macrophages and bovine lacteal polymorphonuclear leukocytes. Infect. Immun. 1976, 14, 11-17.
  • Idoate I., Vander Ley B., Schultz L., Heller M.: Acute phase proteins in naturally occurring respiratory disease of feedlot cattle. Vet. Immunol. Immunopathol. 2015, 163, 221-226.
  • Maeda T., Shibahara T., Kimura K., Wada Y., Sato K., Imada Y., Ishikawa Y., Kadota K.: Mycoplasma bovis-associated suppurative otitis media and pneumonia in bull calves. J. Comp. Pathol. 2003, 129, 100-110.
  • Maunsell F. P., Donovan G. A., Risco C., Brown M. B.: Field evaluation of a Mycoplasma bovis bacterin in young dairy calves. Vaccine 2009, 27, 2781-2788.
  • Nicholas R. A., Ayling R. D., Stipkovits L. P.: An experimental vaccine for calf pneumonia caused by Mycoplasma bovis: clinical, cultural, serological and pathological findings. Vaccine 2002, 20, 3569-3575.
  • Nicholas R. A. J., Ayling R. D.: Mycoplasma bovis: disease, diagnosis and control. Res. Vet. Sci. 2003, 74, 105-112.
  • Soehnlen M. K., Aydin A., Lengerich E. J., Houser B. A., Fenton G. D., Lysczek H. R., Burns C. M., Byler L. I., Hattel A. L., Wolfgang D. R., Jayarao B. M.: Blinded, controlled field trial of two commercially available Mycoplasma bovis bacterin vaccines in veal calves. Vaccine 2011, 29, 5347-5354.
  • Szacawa E., Niemczuk K., Dudek K., Bednarek D., Rosales R., Ayling R.: Mycoplasma bovis infections and co-infections with other Mycoplasma spp. with different clinical manifestations in affected cattle herds in eastern region of Poland. Bull. Vet. Inst. Pulawy 2015, 59, 331-337.
  • Underdown B. J., Schiff J. M.: Immunoglobulin A: strategic defense initiative at the mucosal surface. Annu. Rev. Immunol. 1986, 4, 389-417.
  • Welsh R. D., Dye L. B., Payton M. E., Confer A. W.: Isolation and antimicrobial susceptibilities of bacterial pathogens from bovine pneumonia: 1994-2002. J. Vet. Diagn. Invest. 2004, 16, 426-431.
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.